Published on 24/12/2025
Chain of Custody in Sample Transport – Audit-Proof Guide
Introduction: Why Chain of Custody Matters in Clinical Trials
The movement of clinical trial biospecimens—from site to central lab or biorepository—must be fully traceable to protect data integrity, subject safety, and regulatory compliance. The “chain of custody” ensures that each transfer of a biological sample is documented, authorized, and verifiable, minimizing the risk of tampering, loss, or misidentification.
Both FDA and EMA inspectors evaluate sample transport documentation as part of inspection readiness. An incomplete or non-compliant chain of custody log is considered a major finding and may compromise trial outcomes.
Regulatory Expectations for Sample Chain of Custody
According to ICH GCP E6(R2), all sample handling must preserve the identity and integrity of the sample from collection to analysis. Key compliance factors include:
- Uniquely identifiable sample linked to subject ID and visit
- Documented custody transfers including date, time, and signatory
- Reconciliation of sample receipt with manifest
SOP Requirements for Chain of Custody
The SOP governing biospecimen transport must clearly define:
- Roles and responsibilities of site staff, couriers, and central lab personnel
- Log formats and required data fields for custody transfer
- Criteria for rejecting samples with broken seals or missing documentation
- Corrective action process for custody deviations
- Document retention and integration into the eTMF
Table: Required Fields in Chain of Custody Logs
| Field | Description | Inspection Relevance |
|---|---|---|
| Sample ID | Matches label and CRF | Traceability |
| Date/Time of Handover | Each point of custody change | ALCOA+ principle |
| Transferred From / To | Person or organization | Accountability |
| Signatures | Ink or digital authentication | Audit requirement |
| Condition Remarks | Seal intact, temperature OK, etc. | Sample integrity assurance |
Case Study: FDA Inspection – Custody Gap Finding
During an FDA inspection of a metabolic disorder trial, the agency cited a major deviation where 13 samples shipped from the site lacked documented handover from the principal investigator to the courier. The courier logs only had delivery timestamps, but no corresponding pick-up records.
CAPA Actions Taken:
- Revised SOP to mandate dual sign-off at site departure
- Mandatory use of a courier custody form with preprinted sample IDs
- Retrospective reconciliation between site log, manifest, and lab receipt log
Best Practices for Maintaining Custody Integrity
To ensure regulatory compliance and minimize risk:
- Use tamper-evident packaging with serial number linkage
- Implement real-time scan-based tracking systems with GPS for temperature-sensitive shipments
- Ensure sample packaging includes printed manifest and seal verification stickers
- Request courier service logs with timestamps and names
- Verify central lab reconciliation reports match site manifest
Training and CAPA Readiness
All clinical staff must be trained on proper documentation procedures. Training must include:
- Mock transport scenarios with logbook practice
- Temperature log handling and verification process
- Error correction procedures in case of documentation mistakes
- Response plans for lost or compromised samples
CAPA must be initiated for any gaps in custody documentation and include root cause analysis and trend monitoring.
External Reference
More guidance on secure sample transport is available via the Australian New Zealand Clinical Trials Registry which outlines region-specific biosample logistics best practices.
Conclusion
A robust and auditable chain of custody process is not only a regulatory expectation but a cornerstone of clinical trial credibility. Sponsors and sites must invest in clear SOPs, validated custody documentation, and staff training to prevent sample mishandling, data loss, and inspection findings. Whether using manual forms or integrated eSystems, maintaining a continuous, gap-free custody trail is essential to uphold trust in trial outcomes.